Nuo Therapeutics Secures New Debt Financing and Warrants

Nuo Therapeutics ( (AURX) ) has issued an announcement.

On January 21, 2026, Nuo Therapeutics, Inc. entered into a loan and security agreement with four lenders for up to $1.6 million in debt financing, with $1.0 million funded at initial closing on January 23, 2026 and an additional $600,000 available on September 30, 2026 subject to conditions, to support general working capital needs. The interest-only notes through 2026 carry a 10% rate, rising to 12% if the second tranche is drawn, are secured by a lien on all company assets including intellectual property, and require quarterly principal repayments from March 31, 2027 to a December 31, 2028 maturity, with prepayment obligations and fees triggered by future financings, change-of-control events, or default, all payable in stock warrants rather than cash. As part of the financing, Nuo issued a complex package of equity-linked warrants to the lenders—among them major shareholders and a board member—providing immediate and contingent rights to purchase hundreds of thousands of common shares at $1.50 per share through January 23, 2031, which both strengthens near-term liquidity and meaningfully increases potential future equity dilution and insider ownership if fully exercised.

The most recent analyst rating on (AURX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Nuo Therapeutics stock, see the AURX Stock Forecast page.

More about Nuo Therapeutics

Nuo Therapeutics, Inc. operates in the biotechnology/medical therapeutics space and markets the Aurix product through distributors, indicating a focus on advanced wound care or related therapeutic applications in healthcare markets.

Average Trading Volume: 3,343

Technical Sentiment Signal: Hold

Current Market Cap: $75.48M

For an in-depth examination of AURX stock, go to TipRanks’ Overview page.